Individualising Radiotherapy Through Mechanistic Models

通过机制模型实现个体化放射治疗

• 批准号: MR/Y019792/1
• 负责人: Stephen McMahon
• 金额: $ 75.1万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY019792%2F1
• 关键词: Individualising; Radiotherapy; Through; Mechanistic; Models

Radiotherapy treats cancer through the precise delivery of high doses of radiation to tumours, killing cancerous cells by damaging their DNA. Radiotherapy is highly effective because radiation can be accurately targeted to tumours while avoiding normal tissue, preventing the unwanted side effects which would result from killing healthy cells. The introduction of new advanced treatment techniques and better imaging to improve tumour targeting has significantly improved patient outcomes following radiotherapy. However, while radiotherapy benefits from a high degree of physical personalisation, more can be done to improve treatment outcomes. Cancer is a highly complex disease, associated with a large number of different types of genetic mutation. These mutations can significantly affect the radiation sensitivity of a given patient's cancer. Despite this, all patients with cancer in a particular organ are typically treated with the same dose and treatment schedule. While these doses have been tailored to cancer at a population level, this almost certainly under- and over-treats some patients. If individual radiosensitivity can be precisely defined before treatment, significant improvements in outcome could be achieved, in terms of improved tumour control or reduced side effects, depending on the patient's particular genetics. This fellowship seeks to address this challenge by developing models of how cells respond to radiation, which can accurately predict the sensitivity of an individual's disease based on the mutations present in their particular cancer. In work to date, we have developed models and characterised responses related to DNA repair, and shown that we can effectively predict and quantify quantify how DNA repair failure impacts on radiosensitivity. However, this work has also shown that although loss of DNA repair is important, it only explains a small fraction of the variability between the responses of different cancers and different patients. As a result, this approach needs to be expanded to better understand the range of responses seen in the clinic.In this renewal phase, we will work to better characterise these differences, measuring the impact that changes in other biological processes - such as those related to cell growth and cell death - have on radiation sensitivity, and integrate this into a combined model. We will demonstrate the efficacy of this model using new data generated locally, and then develop a method by which these predictions can be applied in clinical treatment plans, to enable its predictions to be tested in real patient data.If successful, this research programme will deliver a unique tool to enable the tailoring of radiotherapy using both physical and biological factors, offering more personalised therapy and better treatment outcomes for patients suffering from cancer in the future.

放射疗法通过向肿瘤精确输送高剂量辐射，通过破坏癌细胞的 DNA 来杀死癌细胞，从而治疗癌症。放射治疗非常有效，因为放射可以准确地瞄准肿瘤，同时避开正常组织，从而防止因杀死健康细胞而产生的不良副作用。引入新的先进治疗技术和更好的成像技术来改善肿瘤靶向，显着改善了放疗后的患者预后。然而，虽然放射治疗受益于高度的身体个性化，但可以采取更多措施来改善治疗效果。癌症是一种高度复杂的疾病，与大量不同类型的基因突变有关。这些突变可以显着影响特定患者癌症的放射敏感性。尽管如此，所有患有特定器官癌症的患者通常都接受相同的剂量和治疗方案。虽然这些剂量是针对人群水平的癌症量身定制的，但这几乎肯定会导致某些患者治疗不足或过度。如果可以在治疗前精确确定个体的放射敏感性，则可以根据患者的特定遗传学，在改善肿瘤控制或减少副作用方面实现结果的显着改善。该奖学金旨在通过开发细胞如何响应辐射的模型来应对这一挑战，该模型可以根据特定癌症中存在的突变准确预测个体疾病的敏感性。在迄今为止的工作中，我们已经开发了与 DNA 修复相关的模型和特征反应，并表明我们可以有效地预测和量化 DNA 修复失败如何影响放射敏感性。然而，这项工作还表明，尽管 DNA 修复的丧失很重要，但它只能解释不同癌症和不同患者反应之间差异的一小部分。因此，这种方法需要扩展，以更好地了解临床中看到的反应范围。在这个更新阶段，我们将努力更好地描述这些差异，测量其他生物过程变化的影响 - 例如那些相关的生物过程细胞生长和细胞死亡——对辐射敏感性的影响，并将其整合到一个组合模型中。我们将使用本地生成的新数据来证明该模型的功效，然后开发一种方法，将这些预测应用于临床治疗计划，使其预测能够在真实的患者数据中进行测试。如果成功，该研究计划将提供一种独特的工具，能够利用物理和生物因素来定制放射治疗，为未来的癌症患者提供更个性化的治疗和更好的治疗结果。